One August print frames the next 50% — bull scenario 310p, bear 165p, both anchored on the same H1 release.

• Bull scenario (310p, +51%). Adjusted operating margin compounded from 17.7% in 2021 to 22.3% in FY25; FY26 guide ≥23%, FY27 target 24-26%. 180 Medical (59% own-brand US continence channel) and Infusion Care (high-single-digit FY26 growth, multi-year OEM contracts with Tandem, Medtronic, and Ypsomed underwriting the bulk of the FY26 $135-165M growth-capex envelope) are 40% of revenue and visibly defended.
• Bear scenario (165p, -20%). Mason inherited a target softened from "mid-20s by 2026/27" to "closer to 24% by 2027" in his first reporting cycle; H2-25 IFRS op margin compressed to 10.9% from H1's 15.2% on tariffs and FDA spend. Each 100bps shortfall is ~$24M of pre-tax profit.
• The arbiter — 4 August 2026. H1 carries the full ~20bps tariff load and Unomedical FDA remediation; the working-capital build (DSO 53→63d, +$111M payables release) reverses in the same release. Adj margin ≥23% with DSO under 56d would validate the bull setup; sub-22% would trigger consensus cuts and put the 165p path in play.

The 101% cash conversion the buyback rests on is 61% under the prior definition — disclosed only on the call.

• The redefinition. In her first reporting cycle, the new CFO redefined free-cash-flow-to-equity to exclude $121M of "growth capex" (vs $59M restated for FY24). The press release led with "101% conversion." Under the prior definition the number is 61%, as the CFO confirmed on the call. Fifteen percent of variable pay anchors to this metric.
• The working-capital prop. Trade receivables grew 25.1% on revenue +6.6%; payables released $111M as DPO stretched from 139 to 169 days, an eight-year high. The headline OCF of $470M does not survive a payables normalisation, and both items mechanically face their first test in 1H 2026.
• The leverage. The $300M buyback completed in H2-25 — the first material repurchase in CTEC's listed history, $326M in cash outflow including settlement costs — and $140M of dividends together returned $466M against $335M of FCF. The gap was funded with a fresh $500M ten-year unsecured note. Net debt rose $272M to land at the 2.0× target leverage; cash drained to $68M — effectively zero buffer.

Gross margin firm at 56%; the IFRS-to-adjusted gap is largely amortisation that mechanically rolls off.

The $228M IFRS-to-adjusted gap is mostly non-cash: $134M of acquired-intangible amortisation (of which $95M from the 2008 Bristol-Myers Squibb spin-out runs off entirely by mid-2026) and a $72M InnovaMatrix impairment from the January 2026 CMS skin-substitute rate cut. Three-year operating-cash-flow-to-net-income of 2.49× confirms the cash story has substance, but FY25's $111M payables release and 25% receivables build mean the H1 working-capital reversal is the cleanest test of whether the cash machine survives its own tailwinds.

Five months reshaped the C-suite, the shareholder register, and the regulatory perimeter.

Leadership. CEO Karim Bitar took medical leave on 4 August 2025 and died on 27 October 2025; CFO Jonny Mason was elevated to permanent CEO on 6 November 2025, with Group Financial Controller Fiona Ryder confirmed as CFO the same day. Both are insiders, both ran finance, neither has run a healthcare business at scale or been tested as a CEO/CFO pair through a public-markets crisis.

Register. Novo Holdings — the long-standing 7.8% anchor shareholder, board representative until 2023 — exited the entire ~155M-share stake on 17 November 2025 at 227p, a 5.1% discount. The shares are now fully institutional with no holder above 5.2%, and the 20 November volume flush at 6.8× average on a flat-to-down close was textbook distribution.

Regulator. The FDA issued a Warning Letter dated 8 January 2026 to Convatec subsidiary Unomedical (Reynosa, Mexico) citing more than 5,000 insulin-set leak complaints between January 2023 and June 2025, plus more than 41,000 complaints closed without investigation for missing lot numbers. Convatec disclosed the letter on 3 February 2026; no production restriction, but the remediation, partner audits and Infusion Care margin slippage are not yet in consensus.

A trading update in 12 days and a binary H1 print 87 days out, both into a 52-week-low tape.

• 21 May 2026 — AGM trading update. First Mason-era cadence; first chance to reaffirm or walk back the 5-7% organic ex-InnovaMatrix and double-digit adjusted-EPS guides. A confident reaffirmation would test the 234p 200-day average; a walk-back accelerates the bear path into August.
• 4 August 2026 — H1 results. The single most decision-relevant print in CTEC's investable history: adjusted operating margin absorbing the full ~20bps tariff load and Unomedical remediation, the working-capital reversal, and the bridge to the prior FCF-to-equity definition. Bull confirmation conditions: adj margin ≥23.5% with DSO under 56d; bear trigger conditions: sub-22% with DSO over 60d.
• July 2026 — CY2027 Medicare proposed rule. The $127.28/cm² skin-substitute rate that anchors biologic Advanced Wound Care was set for 2026 but the trade body publicly calls it unsustainable. A second cut would broaden the InnovaMatrix narrative across Coloplast Kerecis, Smith+Nephew GRAFIX, and Integra Skin.